Inmed commercializes cannabidivarin (cbdv), expanding its rare cannabinoid portfolio for the health and wellness sector

Vancouver, british columbia and south san francisco, calif., april 21, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched b2b sales of the rare cannabinoid cannabidivarin (“cbdv”) to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its us subsidiary, baymedica llc.
INM Ratings Summary
INM Quant Ranking